Global Information
회사소개 | 문의 | 비교리스트

샤가스병(아메리칸 수면증) : 파이프라인 리뷰

Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 268985
페이지 정보 영문 92 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


샤가스병(아메리칸 수면증) : 파이프라인 리뷰 Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 92 Pages

샤가스병(아메리칸 수면증)이란 트리파노소마 크루지(Trypanosoma cruzi)라는 기생원충에 의해 발병되는 절족동물 매개성 인축공통 감염증입니다. 주요 증상으로 감염 부위의 종창과 발열, 권태감, 체내 통증, 식욕 부진, 구역질·구토, 설사, 선종창 등을 들 수 있습니다. 주요 치료법에는 항기생충 약물요법 등이 있습니다.

세계 각국에서의 샤가스병(아메리칸 수면증)(Chagas Disease (American Trypanosomiasis)) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시의 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

샤가스병(아메리칸 수면증) 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

샤가스병(아메리칸 수면증) 치료제 개발 참여 기업

  • AstraZeneca Plc
  • Bayer AG
  • Daiichi-Sankyo
  • Eisai Inc.
  • GlaxoSmithKline Plc
  • Grupo Praxis Pharmaceutical SA
  • KaloBios Pharmaceuticals Inc
  • Kancera AB
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Sanofi

약제 개요

샤가스병(아메리칸 수면증) : 휴지중인 프로젝트

샤가스병(아메리칸 수면증) : 개발이 중지된 제품

샤가스병(아메리칸 수면증) : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.06.12

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by AstraZeneca Plc, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Cesa Alliance SA, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Collaborations Pharmaceuticals Inc, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Diakonos Research Ltd, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co Ltd, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Evotec SE, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by IC-MedTech Inc, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Oblita Therapeutics BVBA, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Synstar Japan Co Ltd, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Dormant Projects, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease - Pipeline Review, H1 2020, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape.

Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical, Discovery and Unknown stages are 1, 3, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 18 and 5 molecules, respectively.

Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chagas Disease (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chagas Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chagas Disease (American Trypanosomiasis) - Overview
    • Chagas Disease (American Trypanosomiasis) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Bayer AG
    • Cesa Alliance SA
    • Collaborations Pharmaceuticals Inc
    • Daiichi Sankyo Co Ltd
    • Diakonos Research Ltd
    • Eisai Co Ltd
    • Evotec SE
    • GlaxoSmithKline Plc
    • Grupo Praxis Pharmaceutical SA
    • IC-MedTech Inc
    • Novartis AG
    • Oblita Therapeutics BVBA
    • Sanofi
    • Synstar Japan Co Ltd
  • Chagas Disease (American Trypanosomiasis) - Drug Profiles
    • (sodium ascorbate + menadione sodium bisulfite) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benznidazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chagas disease (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chagas disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chagas disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chagas disease vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cz-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cz-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DNDI-0690 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EPLBS-1246 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EPLBS-967 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fexinidazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosravuconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNF-6702 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-777 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAO-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nifurtimox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pyronaridine tetraphosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-114137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Protozoal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CYP51A1 for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for African Trypanosomiasis, Chagas Disease and Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Pex14 for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VNI - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chagas Disease (American Trypanosomiasis) - Dormant Projects
  • Chagas Disease (American Trypanosomiasis) - Discontinued Products
  • Chagas Disease (American Trypanosomiasis) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 30, 2020: Bayer application for nifurtimox to treat pediatric patients with Chagas disease submitted for approval in US
      • Mar 14, 2019: Phase III clinical trial with Bayer's nifurtimox demonstrates safety and efficacy of new formulation to treat children with Chagas disease
      • Jun 22, 2017: UTEP Scientists Awarded Patent for Chagas Disease Vaccine
      • Nov 15, 2016: Bayer to Fight Chagas Disease in Children
      • Aug 08, 2016: A single compound could treat three parasitic diseases
      • Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
      • Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease
      • Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy
      • May 03, 2013: Funding boost for GSK's open innovation research into diseases affecting the developing world
      • Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease
      • Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q